HomeTag Stuart Therapeutics

Stuart Therapeutics, Inc. announces licensing agreement with Aju Pharm Co. Ltd.

STUART, Fla., Jan. 3, 2023 /PRNewswire/ — Stuart Therapeutics, Inc., (hereinafter Stuart) announces that it has entered into a license agreement with AJU Pharm Co. Ltd. (hereinafter AJU), for Stuart’s clinical stage drug candidate ST-100. Under this agreement, AJU has the exclusive right to develop and commercialize ST-100 for South Korean and certain Southeast Asian markets in exchange for certain...

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100

Stuart Therapeutics, Inc. Announces Successful Phase 2 Clinical Trial Results of its Novel Dry Eye Candidate ST-100   – Achieved FDA Pre-Approved Single Primary Endpoint After 28 Days of Administration – Improvement in Total Ocular Discomfort after 14 Days   STUART, Fla., Jan. 3, 2022 /PRNewswire/ — Stuart Therapeutics, Inc. (STUART), a clinical stage, innovative ophthalmic...

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease

Stuart Therapeutics, Inc. Announces Completion of Patient Enrollment in Phase 2 Clinical Trial for Dry Eye Disease STUART, Fla., Sept. 8, 2021 /PRNewswire/ — Stuart Therapeutics, Inc. (“Stuart“), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced that it has completed patient enrollment in its Phase 2...

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital

Stuart Therapeutics Completes its $11M Series A Round, led by InFocus Capital Partners, WARF and MiMo Capital Stuart Therapeutics, Inc. (“Stuart”), a clinical stage biopharmaceutical company conducting research and development of unique peptide therapeutics for ophthalmic diseases, today announced the completion of an $11 million Series A round of capital investment. The round was led...